For manufacturers

What we do

More exports. More markets. Less of the work.

01

Grow your exports

More volume, more orders, steady reorders. We keep your lines moving long after launch.

02

Launch in new markets

We pick the market, register your products and sign the right distributor.

03

Win more of the markets you’re in

Sharper pricing, better partners and more of your lines on the shelf.

Behind it: partners, registration, pricing and sales, run by our own team in every market.

Why exports stall

Most launches fail before the first shipment.

Not because of the product or the price. Because of the wrong market, the wrong partner, or a registration nobody planned.

Partner The distributor was picked because they replied

A fast reply says nothing about whether they sell your category, or already push three rival lines.

Evidence The market was judged from a brochure

The national register shows which categories are crowded and which are empty. Most people never read it.

Sequence Registration came last

Plan the route first and whole categories open up. Plan it last and you find the dead ends after the money is spent.

Control After signing, you lose sight of it

Orders come or they don’t, and nobody can tell you why. Who registered against you, what the shelf price became: all of it goes dark.

What we run

Eight things we run, so you don’t have to.

Your export team on the ground, not a broker who makes an introduction and disappears.

01

Find the right distributor

Every distributor is profiled from the register: what they hold, in which categories, from whom. Shortlists are built on evidence.

Ranked by real portfolio overlap with your products
Category strength and national standing, not self-description
Who they already represent, and where you would conflict
Warm introduction and negotiation support through to agency

02

Choose what to launch, and where

Your catalogue mapped against each market’s register and essential medicines list, and ranked by what is genuinely open.

Your lines scored per market on supplier depth and demand
The thin positions where you would set price rather than match it
Gaps worth developing, with the volume signal behind each
Products to leave out, and the reason, in writing

03

Get registered

Route, dossier and timeline set before you commit, then carried through to submission. Where the plant must be approved first, we plan for it.

Country-by-country route, requirement and realistic timeline
Dossier compiled, gaps in your existing pack identified early
Zone IVb stability and labelling requirements checked up front
Agency documentation, legalisation and filing handled locally

04

Pass every quality check

GMP, CPP and certification packs checked against local rules before a buyer or regulator sees them.

GMP, CPP and certification pack reviewed against each market's rules
Animal-origin, halal and excipient declarations prepared where required
Batch documentation and CoA formats aligned to local expectations
Queries from the regulator handled rather than forwarded

05

Price to win

Real selling prices per market and per pack, from registered prices and live competitor quotes. Not a margin worked backwards.

Landed and shelf price benchmarks against real competitors
Where you hold leverage and where you would be undercut
Pack and presentation choices that change the price bracket
Tender and institutional pricing where the market is programme-led

06

Drive sales after launch

A registration isn’t a sale. We work with the distributor’s team on who details your product, to whom, and with what.

Launch planning with the distributor's own sales team
Promotional material and product training prepared locally
Target prescriber and institution mapping by geography
Reorder tracking, with the diagnosis when a line slows

07

Watch the market for you

New registrations, competitors and procurement signals in your categories, every week, in every market.

New registrations in your categories, and who took them
Competitors entering or lapsing out of a molecule
Essential medicines list changes and procurement signals
Renewal dates tracked ahead of the deadline, not after it

08

One contact, weekly reports

One point of contact for every market, and a written update on each one. No chasing four distributors in three time zones.

Weekly written reporting per market
Order, stock and reorder visibility from the distributor side
Quarterly review of what to push, fix or drop
Escalation handled by us, in market, in person where needed

And the part that is not a feature

On the ground, and paid on results.

We earn when your product sells, not when we make an introduction. If a market won’t work, you hear it from us early.

What this looks like

12 eye-care medicines. Zero suppliers in the country.

We read one market’s full register against its essential medicines list. Twelve eye-care medicines had no registered supplier at all. Not a thin market: an empty one.

Weeks earlier, a large distributor there had asked us for one of them by name. For a maker of sterile eye drops, that is an open category with a buyer already waiting. It’s the kind of gap we look for in your portfolio.

Essential medicines cross-referenced664

Ophthalmic molecules with no supplier12

Registered in the country0

Where we sell

Seven markets. We work each one ourselves.

Offices in Lahore, London and Almaty. If we don’t cover your market, we’ll tell you on the first call.

East Africa

Tanzania, Kenya and neighbours. Register-led, tender-heavy, and the market we know in the most depth.

Sudan and the Horn

Site registration before product registration, a large import dependency, and an established South Asian supply route.

Central Asia

Reached through our Almaty office, with different documentation norms and a very different competitive set.

Selected Asian and MENA markets

Taken on where a molecule, a certification or an existing relationship makes the route real.

1/7markets we serve

East Africa Sudan and the Horn Central Asia · Kazakhstan Selected Asian and MENA

One of our seven markets · Kazakhstan

Spotlight: Kazakhstan.

One of our seven markets, shown in full. A $2.5bn market that imports 85% of what it sells, run by our team in Almaty from first dossier to reorder.

$2.5bnMedicines market, 2025

+16%Forecast growth, 2026

85%Of sales value is imported

57%Of value sold through pharmacies

Pharmacies

About 9,000 outlets. Chains hold three-quarters of retail, so a few listings reach most of the country.

One state buyer

One distributor buys about $1.1bn a year for free and insured care, and publishes every lot. We have read 88,000+ of them.

Hospitals

They buy injectables and diagnostics themselves, and supply gaps are frequent.

Physicians

1,000+ in our network. Protocol mapping, then targeting by specialty and region.

What a manufacturer has to know in Kazakhstan. EAEU rules apply to all new medicines from 2026. Russian and Kazakh on every label. Serialised marking since July 2024. VAT on eligible medicines is 5% in 2026 and 10% from 2027. Local producers get tender priority, so we position you where there is a way in.

Beyond Kazakhstan

One dossier. Four markets.

Kazakhstan can act as the EAEU reference state, so Belarus, Kyrgyzstan and Armenia can recognise the same dossier. We run every step.

EAEU member	People	Medicines market	Route
Kazakhstan	about 20.5M	$2.5bn (2025)	Reference state
Belarus	about 9M	$1.5bn (2021)	Recognition
Kyrgyzstan	about 7M	$340M imported (2025)	Recognition
Armenia	about 3M	€155M retail (2021)	Recognition

Reference stateKZ

Recognition states3

People across the four~40M

Pricing, language, pharmacovigilanceRun by us

Recognition is filed country by country. Latest public figures found; years and bases differ by country. Populations rounded. Kyrgyz imports converted at 87.45 soms per US$.

Exporting from

Making medicines in Bangladesh, Turkey, Pakistan or Egypt?

We work with plants there every day. We already know which of your products will clear registration where, who will sell them, and at what price. One call tells you if your portfolio has a route.

BangladeshTurkeyPakistanEgyptElsewhere — ask us

Book a call Message on WhatsApp Twenty minutes, no preparation needed. Bring your product list.

Control

Who holds your registration?

It decides who controls your product in each market. We settle it with you before any paperwork.

Stays yours You

The product, the dossier, the plant and the brand are yours throughout. Nothing in how we work changes that, in any market.

The part that matters The registration holder

In most of our markets the certificate names a local party, and whoever is named controls that product on the ground. Who it should be differs by country — and it is decided before filing, not after.

Replaceable Your distributor

Stocks it, sells it, details it. If they stop performing they can be changed — provided the step to their left was set up with that in mind.

The registration never goes in Nazryx’s name. We are your agent, not a party that holds your product hostage. Before anything is filed we tell you who should hold it in that market, and exactly what changing partner would involve later.

The output

Every market comes back as one clear report.

What is open, who could sell it, how to register it and what it is worth. Written to act on, not to file.

Ask and we’ll walk you through a real one.

Ask for a sample

Market readConfidential

01

The market, honestly assessed

02

Your portfolio ranked against it

03

Distributor shortlist, with why

04

Registration route and timeline

05

Pricing position per line

06

What we would do next

Prepared for one manufacturer. Not circulated.

The partnership

What we put in writing.

Before you hand us your products, these are on paper.

No competing line in your category

We will not represent a directly competing product in the same category in the same market. You are not one of four names in a folder.

The registration never goes in our name

We are your agent, not a party holding your product. Who should hold the certificate in each market is settled with you before anything is filed.

We tell you when not to enter

If a market is crowded or the economics do not work, you hear that before you pay for a dossier. It costs us less to say so than to run a filing that leads nowhere.

Your documentation stays yours

Portfolio, pricing and certification pack stay confidential and stay in your control. If we part ways, nothing of yours stays behind with us.

Omar NazirPrincipal Director, Nazryx — these are commitments, not preferences.

How it starts

See the market read before you sign anything.

The first piece of work is evidence, not a contract. If the register says your products don’t fit, you hear it first.

Before we start

A scoping call

Twenty minutes on your portfolio, your certifications and which markets you are curious about. If we are not the right fit we will say so on the call rather than after an invoice.

Week 1

We load your portfolio

Product list, dosage forms, certifications, existing export markets and any registrations you already hold. Mostly exports you already have; none of it needs tidying first.

Weeks 2–3

The market read

Your catalogue against the register and essential medicines list of each target market: what is open, what is crowded, what the registration route and timeline looks like, and what it is worth.

Weeks 3–5

The distributor shortlist

Named companies ranked on portfolio fit and category standing, with what they already carry and where you would conflict. Introductions made and negotiations supported by us.

From week 5

Registration and launch

Dossier compiled, filing run in market, and the launch worked with the distributor's sales team once approval lands. Weekly reporting runs from here on.

Fit

We would rather say no early.

We take on a small number of manufacturers because each one means real regulatory and commercial work in market. It is worth being direct about where this fits and where it does not.

This works well if you

Manufacture finished pharmaceuticals to a recognised GMP standard
Want to enter or grow in African, Asian or Middle Eastern markets
Have a real portfolio — enough lines that which ones to push actually matters
Can support registration with a dossier and the documentation behind it
Would rather have one accountable partner than five distributors you cannot see

This is the wrong fit if you

Want a list of buyer contacts to email yourself — we represent, we do not sell leads
Need a single container moved once, with no interest in the market after it
Cannot share your product list and certifications — without them the read is generic
Are looking for someone to take your existing distributor relationship and simply re-paper it

Questions

What manufacturers ask first.

Are you an agent, a consultant, or a distributor?

We act as your trade and regulatory arm in the markets we cover. We do not buy and resell your product, and we do not take title to stock. We find and manage the distributor who does, and we run the registration and market work around it.

In practice that means you get the control of a direct relationship with the distributor, and we are the party accountable for the market working.

How are you paid?

Commission on business that actually moves, agreed per market before anything starts. Where a registration programme requires sustained regulatory work ahead of any revenue, that is scoped and agreed separately — we will not dress up a year of filing work as free.

What we will not do is charge for an introduction. If nothing sells, we have not earned.

We already have a distributor in that market.

Then the useful question is whether they are the right one, and that is answerable from the register rather than from the relationship. We can show you where they actually rank in your categories, what else they carry, and whether your line is a priority for them or a shelf filler.

Often the answer is that the distributor is fine and the problem is elsewhere — pricing, registration timing, or nobody detailing the product. We would rather fix that than replace them.

How long does registration actually take?

It varies by market and we will give you a real number per country rather than an average. What is consistent is the sequence: in several of our markets the manufacturing site has to be registered before any product from it can be filed, so a plant that is not yet approved is the first thing to fix, not the dossier.

We tell you the route and the timeline before you spend anything on it.

What do you need from us to start?

Your product list with dosage forms and strengths, your GMP and certification pack, the markets you already export to, and one person we can ask questions of. That is enough for the market read.

Dossiers and legalised documents come later, and only for the products you decide to take forward.

Start with the market read.

Send us your product list and tell us which market you are curious about. We will come back with what is open, what is crowded, and which distributors would actually sell it — before either of us talks about an agreement.

Book a call with us Email instead Nazryx — a company of Nazir & Company International (PVT) Limited

Launch into more markets, without the hassle.